Jo Sang Kyung, Rosner Mitchell H, Okusa Mark D
Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Clin J Am Soc Nephrol. 2007 Mar;2(2):356-65. doi: 10.2215/CJN.03280906. Epub 2007 Jan 17.
Current strategies to limit the extent of injury in acute renal failure are based on extensive studies that identified cellular and molecular mechanisms of acute kidney injury. Despite successes in various animal models, translation to human studies has failed or studies are inconclusive. This review describes past failures and barriers to successful clinical trials. It also focuses on promising preclinical studies using novel compounds that currently are in or close to human investigation. Implementation of previous or novel compounds in well-designed clinical trials provides hope for the successful treatment of this devastating disorder.
目前限制急性肾衰竭损伤程度的策略是基于广泛的研究，这些研究确定了急性肾损伤的细胞和分子机制。尽管在各种动物模型中取得了成功，但向人体研究的转化却失败了，或者研究结果尚无定论。这篇综述描述了过去的失败以及成功开展临床试验的障碍。它还聚焦于使用目前正在或即将进入人体研究阶段的新型化合物进行的有前景的临床前研究。在精心设计的临床试验中应用先前的或新型化合物为成功治疗这种毁灭性疾病带来了希望。
